10x Genomics, Inc. (TXG) experienced a significant intraday plummet of 8.52% on Friday, as investors reacted to the company's latest quarterly financial results.

The sharp decline followed the release of 10x Genomics' first-quarter earnings report, which showed revenue falling 3% year-over-year to $150.84 million. While the company's adjusted loss of 10 cents per share beat analyst expectations, the revenue decline and a dramatic 94% plunge in license and royalty revenue to just $947,000 appear to have concerned investors. The mixed results, with revenue decreasing despite cost controls and margin improvements, triggered selling pressure during the trading session.

Analyst reactions to the earnings were mixed, with Piper Sandler maintaining a Hold rating and $20 price target on the stock, while Deutsche Bank raised its price target from $17 to $23. The contrasting analyst views and the underlying revenue challenges highlighted in the quarterly report contributed to the stock's volatility during Friday's trading.